Laurus Labs CEO, MD, chairman, board of directors and AGM
NSE: LAURUSLABSBSE: 540222Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,002.50.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and dividend.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,06,442 Cr171st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 24 Jul 2026
- 97.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 Apr 2026
- 20.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.10%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 24 Jul 2026
- 22.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 24 Jul 2026
- 19.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 Apr 2026
- 0.44
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 18,93,71345.3% delivered
Laurus Labs board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonRAVINDRANATH KANCHERLA
- Chief executiveCHAVA SATYANARAYANA
- Company Secretary and Compliance OfficerG Venkateswar Reddy
10 directors5 independent5 executive
- RAVINDRANATH KANCHERLA · ChairpersonIndependent · joined May 2017 · reappointed May 2022 · 112 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- CHAVA SATYANARAYANA · Chief executiveExecutive · joined Jan 2006 · reappointed Apr 2025 · 1 listed board
- VENKATA RAVI KUMAR VANTARAMExecutive · joined Nov 2006 · reappointed Apr 2025 · 1 listed board · 2 committee seats
- VENKATA LAKSHMANA RAO CHUNDURUExecutive · joined Mar 2018 · reappointed Mar 2023 · 1 listed board · 1 committee seat
- KRISHNA CHAITANYA CHAVAExecutive · joined Apr 2024 · 1 listed board
- SOUMYA CHAVAExecutive · joined Apr 2024 · 1 listed board
- KARNAM SEKARIndependent · joined Apr 2024 · reappointed Apr 2024 · 29 months as independent · 2 listed boards · 2 as independent · 4 committee seats, 2 as chair
- RAMESH SUBRAHMANIANIndependent · joined Jul 2024 · 26 months as independent · 1 listed board · 1 as independent · 1 committee seat
- SHEKHAR CHINTAMANI MANDEIndependent · joined Jul 2026 · 3 months as independent · 2 listed boards · 2 as independent · 1 committee seat
- SUTAPA BANERJEEIndependent · joined Jul 2026 · 3 months as independent · 6 listed boards · 6 as independent · 7 committee seats, 2 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
2 directors who left
- RAJESH KOSHY CHANDY, left 27 Jul 2026: Tenure Completion
- ARUNA RAJENDRA BHINGE, left 7 Jul 2026: Tenure Completion
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 24 Jul 202610 of 11 present5 independent · 84 days in between
- 30 Apr 202610 of 10 present5 independent
Audit Committee
Chair KARNAM SEKAR
RAMESH SUBRAHMANIAN, SUTAPA BANERJEE
- 24 Jul 20263 of 4 present3 independent · 84 days in between
- 30 Apr 20264 of 4 present4 independent
Nomination and remuneration committee
Chair KARNAM SEKAR
RAVINDRANATH KANCHERLA, RAMESH SUBRAHMANIAN
- 30 Apr 20264 of 4 present4 independent
Stakeholders Relationship Committee
Chair RAVINDRANATH KANCHERLA
VENKATA LAKSHMANA RAO CHUNDURU, VENKATA RAVI KUMAR VANTARAM
- 29 Apr 20263 of 3 present1 independent
Risk Management Committee
Chair CHAVA SATYANARAYANA
VENKATA RAVI KUMAR VANTARAM, VENKATA LAKSHMANA RAO CHUNDURU, KRISHNA CHAITANYA CHAVA, SOUMYA CHAVA, RAMESH SUBRAHMANIAN
- 31 Jul 20266 of 6 present1 independent
Corporate Social Responsibility Committee
Chair VENKATA RAVI KUMAR VANTARAM
VENKATA LAKSHMANA RAO CHUNDURU, SOUMYA CHAVA, SHEKHAR CHINTAMANI MANDE
- 30 Apr 20264 of 4 present1 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Deloitte Haskins and Sells LLPPeer-review certificate valid to Jul 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Laurus Labs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Laurus Labs dividend history
Annual general meeting, 2 Jul 2026
2,98,624 shareholders on the register on 25 Jun 2026; present: 6 promoters and 102 others; votes counted by Y. RAVI PRASADA REDDY / RPR & ASSOCIATES.The company's voting result (opens in a new tab)
Adoption of the: (a) audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, the reports of Board of Directors and Auditors thereon (b) audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, the reports of Board of Directors and Auditors thereonMoreLess
Ordinary99.75% for0.25% againstAgainst: promoters 0.00% · institutions 0.54% · other public 0.00%
Turnout: all 74.96% · promoters 100.00% · institutions 84.27% · other public 40.56%
- Aproval and ratification of the 1st interim dividend on equity shares @ Re. 0.80 per equity share paid for the financial year 2025-26.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.56%
- Aproval and ratification of the 2nd interim dividend on equity shares @ Re. 1.20 per share for the financial year 2025-26.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.56%
- Re-appointment of Mr. Krishna Chaitanya Chava (DIN: 06831883), a Director, who retires by rotation and, being eligible, offers himself, for re-appointmentOrdinary99.29% for0.71% against
Against: promoters 0.00% · institutions 1.53% · other public 0.02%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.56%
- Re-appointment of Mrs. Soumya Chava (DIN: 06831892), a Director, who retires by rotation and, being eligible, offers herself, for re-appointment.Ordinary99.29% for0.71% against
Against: promoters 0.00% · institutions 1.52% · other public 0.02%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.56%
- Approval of the appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454) as an Independent Director of the CompanySpecial100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.56%
- Approval of the appointment of Mrs. Sutapa Banerjee (DIN:02844650) as an Independent Director of the CompanySpecial91.65% for8.35% against
Against: promoters 0.00% · institutions 17.96% · other public 0.00%
Turnout: all 74.98% · promoters 100.00% · institutions 84.31% · other public 40.56%
- Approval of payment of remuneration to the Non-Executive Director(s) including Independent Director(s) of the CompanyOrdinary88.86% for11.14% against
Against: promoters 0.00% · institutions 23.93% · other public 0.01%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.55%
- Approval of the remuneration payable to cost auditors for the financial year 2026-27Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 75.06% · promoters 100.00% · institutions 84.51% · other public 40.56%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 26 Jun 2025, 13 resolutions
2,90,986 shareholders on the register on 19 Jun 2025; present: 5 promoters and 104 others; votes counted by Y. RAVI PRASADA REDDY / RPR & ASSOCIATES.The company's voting result (opens in a new tab)
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2025, the reports of Board of Directors and Auditors thereonOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.03% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2025 and report of Auditors thereon.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.03% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- To approve and ratify the 1st interim dividend on equity shares @ Rs.0.40 per share already paid for the Financial Year 2024-25.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- To approve and ratify the 2nd interim dividend on equity shares @ Rs.0.80 per share already paid for the Financial Year 2024-25.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- To appoint a Director in place of Dr. Satyanarayana Chava (DIN: 00211921) who retires by rotation and, being eligible, offers himself, for re-appointment.Ordinary99.64% for0.36% against
Against: promoters 0.00% · institutions 0.79% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- To appoint a Director in place of Dr. C.V. Lakshmana Rao (DIN: 06885453) who retires by rotation and, being eligible, offers himself, for re-appointment.Ordinary99.87% for0.13% against
Against: promoters 0.00% · institutions 0.28% · other public 0.01%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE THE REMUNERATION PAYABLE TO COST AUDITORS FOR THE FINANCIAL YEAR ENDING 2025-26Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE THE APPOINTMENT OF SECRETARIAL AUDITORS OF THE COMPANYOrdinary99.75% for0.25% against
Against: promoters 0.00% · institutions 0.55% · other public 0.04%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE RE-APPOINTMENT OF DR. SATYANARAYANA CHAVA (DIN: 00211921) AS AN EXECUTIVE DIRECTOR & CEO OF THE COMPANYSpecial92.11% for7.89% against
Against: promoters 0.00% · institutions 17.38% · other public 0.01%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE RE-APPOINTMENT OF MR. V.V. RAVI KUMAR (DIN: 01424180) AS AN EXECUTIVE DIRECTOR & CFO OF THE COMPANYSpecial99.58% for0.42% against
Against: promoters 0.00% · institutions 0.92% · other public 0.00%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE MODIFICATION OF TERMS OF EMPLOYMENT CONTRACT OF DR. LAKSHMANA RAO CV, (DIN: 06885453) WHOLE-TIME DIRECTOR OF THE COMPANYSpecial98.95% for1.05% against
Against: promoters 0.00% · institutions 2.30% · other public 0.01%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE MODIFICATION OF TERMS OF EMPLOYMENT CONTRACT OF MR. KRISHNA CHAITANYA CHAVA, (DIN: 06831883) WHOLETIME DIRECTOR OF THE COMPANYSpecial94.88% for5.12% against
Against: promoters 0.00% · institutions 11.29% · other public 0.01%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
- TO APPROVE MODIFICATION OF TERMS OF EMPLOYMENT CONTRACT OF MRS. SOUMYA CHAVA, (DIN: 06831892) WHOLE-TIME DIRECTOR OF THE COMPANYSpecial94.88% for5.12% against
Against: promoters 0.00% · institutions 11.29% · other public 0.01%
Turnout: all 77.76% · promoters 100.00% · institutions 94.19% · other public 42.57%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 3 Oct 2024, 1 resolution
The company's voting result (opens in a new tab)
- Appointment of Mr. Ramesh Subrahmanian (DIN: 02933019) as a Non-executive Independent Director of the CompanySpecial99.62% for0.38% against
Against: promoters 0.00% · institutions 0.63% · other public 0.30%
Turnout: all 62.45% · promoters 90.19% · institutions 93.82% · other public 3.64%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 11 Jul 2024, 11 resolutions
Present: 5 promoters and 101 others.The company's voting result (opens in a new tab)
- To consider and adopt the audited Standalone FinancialnStatements of the Company for the Financial Year endednMarch 31, 2024, the reports of Board of Directors andnAuditors thereonOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 76.17% · promoters 99.99% · institutions 92.94% · other public 39.68%
- To consider and adopt the audited Consolidated FinancialnStatements of the Company for the Financial Year endednMarch 31, 2024 and report of Auditors thereon.Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 76.17% · promoters 99.99% · institutions 92.94% · other public 39.68%
- To approve and ratify the interim dividend on equity shares @nRs. 0.40 per share already paid for the Financial Year 2023-24.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 76.17% · promoters 99.99% · institutions 92.96% · other public 39.68%
- To approve and ratify the 2nd interim dividend on equitynshares @ Rs. 0.40 per share already paid for the Financial Yearn2023-24.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 76.17% · promoters 99.99% · institutions 92.96% · other public 39.68%
- To appoint a Director in place of Mr. V V Ravi Kumar (DINn01424180) who retires by rotation and, being eligible, offersnhimself, for re-appointment.OrdinaryPromoters have an interest in it99.73% for0.27% against
Against: promoters 0.00% · institutions 0.54% · other public 0.01%
Turnout: all 74.70% · promoters 94.31% · institutions 92.94% · other public 39.68%
- TO APPROVE THE REMUNERATION PAYABLEnTO COST AUDITORS FOR THE FINANCIAL YEARnENDING 2024-25Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.01%
Turnout: all 76.17% · promoters 99.99% · institutions 92.94% · other public 39.68%
- APPOINTMENT OF Mr. KRISHNA CHAITANYAnCHAVA AS DIRECTOROrdinaryPromoters have an interest in it91.40% for8.60% against
Against: promoters 0.00% · institutions 12.49% · other public 0.15%
Turnout: all 53.14% · promoters 11.10% · institutions 92.94% · other public 39.68%
- APPOINTMENT OF MS. SOUMYA CHAVA ASnDIRECTOROrdinaryPromoters have an interest in it98.43% for1.57% against
Against: promoters 0.00% · institutions 2.18% · other public 0.27%
Turnout: all 53.14% · promoters 11.10% · institutions 92.94% · other public 39.68%
- TO APPROVE THE APPOINTMENT OF MR.nKRISHNA CHAITNANYA CHAVA (DIN 06831883)nAS EXECUTIVE DIRECTOR OF THE COMPANYSpecialPromoters have an interest in it91.67% for8.33% against
Against: promoters 0.00% · institutions 12.10% · other public 0.16%
Turnout: all 53.14% · promoters 11.10% · institutions 92.94% · other public 39.68%
- TO APPROVE THE APPOINTMENT OF MS. SOUMYAnCHAVA (DIN 06831892) AS EXECUTIVE DIRECTORnOF THE COMPANYSpecialPromoters have an interest in it98.74% for1.26% against
Against: promoters 0.00% · institutions 1.74% · other public 0.28%
Turnout: all 53.14% · promoters 11.10% · institutions 92.94% · other public 39.68%
- TO APPROVE THE APPOINTMENT OF MR.nKARNAM SEKAR AS INDEPENDENT DIRECTORnFOR A PERIOD OF 5 YEARSSpecial99.62% for0.38% against
Against: promoters 0.00% · institutions 0.79% · other public 0.01%
Turnout: all 76.17% · promoters 99.99% · institutions 92.94% · other public 39.68%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 14 Jul 2023, 8 resolutions
Present: 4 promoters and 88 others.The company's voting result (opens in a new tab)
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023, the reports of Board of Directors and Auditors thereonOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.69% · promoters 99.96% · institutions 88.83% · other public 35.81%
- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2023 and report of Auditors thereon.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.69% · promoters 99.96% · institutions 88.83% · other public 35.81%
- To approve and ratify the interim dividend on equity shares @ Rs. 0.80 per share already paid for the Financial Year 2022-23.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.68% · promoters 99.96% · institutions 88.83% · other public 35.78%
- To approve and ratify the 2nd interim dividend on equity shares @ Rs. 1.20 per share already paid for the Financial Year 2022-23.OrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 70.69% · promoters 99.96% · institutions 88.83% · other public 35.80%
- To appoint a Director in place of Dr. Satyanarayana Chava (DIN 00211921) who retires by rotation and, being eligible, offers himself, for re-appointment.OrdinaryPromoters have an interest in it97.98% for2.02% against
Against: promoters 0.00% · institutions 3.42% · other public 0.00%
Turnout: all 44.83% · promoters 14.83% · institutions 80.61% · other public 35.81%
- To appoint a Director in place of Dr. Chunduru Venkata Lakshmana Rao (DIN 06885453) who retires by rotation and, being eligible, offers himself, for re-appointmentOrdinaryPromoters have an interest in it99.67% for0.33% against
Against: promoters 0.00% · institutions 0.76% · other public 0.01%
Turnout: all 68.16% · promoters 90.64% · institutions 88.83% · other public 35.81%
- To approve the remuneration payable to Cost Auditors for the financial year ending 2023-24OrdinaryPromoters have an interest in it99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.07%
Turnout: all 70.69% · promoters 99.96% · institutions 88.83% · other public 35.81%
- To Approve the appointment of Ms. Soumya Chava as Head-CommercialOrdinaryPromoters have an interest in it84.09% for15.91% against
Against: promoters 0.00% · institutions 26.95% · other public 0.05%
Turnout: all 44.94% · promoters 15.23% · institutions 80.61% · other public 35.81%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Postal ballot, 9 Mar 2023, 1 resolution
The company's voting result (opens in a new tab)
- RE-APPOINTMENT OF DR. VENKATA LAKSHMANA RAO CHUNDURU (DIN 06885453) AS EXECUTIVE DIRECTOR OF THE COMPANYSpecialPromoters have an interest in it99.94% for0.06% against
Against: promoters 0.00% · institutions 0.10% · other public 0.06%
Turnout: all 63.68% · promoters 90.67% · institutions 89.46% · other public 26.17%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 30 Jun 2022, 10 resolutions
Present: 4 promoters and 120 others.The company's voting result (opens in a new tab)
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022, the reports of Board of Directors and Auditors thereonOrdinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.41% · promoters 99.98% · institutions 86.97% · other public 21.97%
- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2022 and report of Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.41% · promoters 99.98% · institutions 86.97% · other public 21.97%
- To approve and ratify the 1st interim dividend on equity shares Rs. 0.80 per share already paid for the Financial Year 2021-22.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.43% · promoters 99.98% · institutions 87.03% · other public 21.97%
- To approve and ratify the 02nd interim dividend on equity shares Rs. 1.20 per share already paid for the Financial Year 2021-22.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 63.42% · promoters 99.98% · institutions 87.00% · other public 21.97%
- To appoint a Director in place of Mr. Chandrakanth Chereddi (DIN 06838798) who retires by rotation and, being eligible, offers himself, for re-appointment.OrdinaryPromoters have an interest in it99.34% for0.66% against
Against: promoters 0.00% · institutions 1.54% · other public 0.04%
Turnout: all 63.42% · promoters 99.96% · institutions 87.00% · other public 21.97%
- To appoint a Director in place of Mr. V V Ravi Kumar (DIN 01424180) who retires by rotation and, being eligible, offers himself, for re-appointment.OrdinaryPromoters have an interest in it99.93% for0.07% against
Against: promoters 0.00% · institutions 0.16% · other public 0.01%
Turnout: all 61.94% · promoters 94.57% · institutions 87.00% · other public 21.97%
- Reappointment of Statutory AuditorOrdinary97.85% for2.15% against
Against: promoters 0.00% · institutions 5.04% · other public 0.03%
Turnout: all 63.42% · promoters 99.98% · institutions 87.00% · other public 21.97%
- TO APPROVE THE REMUNERATION PAYABLE TO COST AUDITORS FOR THE FINANCIAL YEAR ENDING 2022-23Ordinary98.13% for1.87% against
Against: promoters 0.00% · institutions 4.39% · other public 0.03%
Turnout: all 63.42% · promoters 99.98% · institutions 87.00% · other public 21.97%
- REAPPOINTMENT OF Dr. MALEMPATI VENUGOPALA RAO AS INDEPENDENT DIRECTOR FOR A FURTHER PERIOD OF 2 YEARSSpecial98.85% for1.15% against
Against: promoters 0.00% · institutions 2.81% · other public 0.04%
Turnout: all 61.23% · promoters 99.98% · institutions 79.97% · other public 21.95%
- REAPPOINTMENT OF Dr. RAVINDRANATH KANCHERLA AS INDEPENDENT DIRECTOR FOR A FURTHER PERIOD OF 5 YEARSSpecial99.59% for0.41% against
Against: promoters 0.00% · institutions 0.99% · other public 0.05%
Turnout: all 61.24% · promoters 99.98% · institutions 79.97% · other public 21.97%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Annual general meeting, 15 Jul 2021, 16 resolutions
Present: 5 promoters and 278 others.The company's voting result (opens in a new tab)
- Adoption of the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2021, the reports of Board of Directors and Auditors thereonOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.49% · promoters 99.98% · institutions 55.92% · other public 38.02%
- Adoption of the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2021 and report of Auditors thereonOrdinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.49% · promoters 99.98% · institutions 55.92% · other public 38.01%
- Approval and ratification of the 1st interim dividend on equity shares @ Rs.0.80 already paid for FY 21Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.54% · promoters 99.98% · institutions 56.12% · other public 38.01%
- Approval and ratification of the 2nd interim dividend on equity shares @ Rs.0.40 already paid for FY 21Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.54% · promoters 99.98% · institutions 56.12% · other public 38.01%
- Approval and ratification of 3rd interim dividend on equity shares @ Rs.0.80 for the FY21Ordinary99.99% for0.01% against
Against: promoters 0.00% · institutions 0.00% · other public 0.04%
Turnout: all 59.54% · promoters 99.98% · institutions 56.12% · other public 38.01%
- Reappointment of Dr.Satyanarayana Chava (DIN 00211921) who retires by rotation and, being eligible, offers himself for reappointmentOrdinaryPromoters have an interest in it97.96% for2.04% against
Against: promoters 0.00% · institutions 5.14% · other public 0.04%
Turnout: all 36.27% · promoters 14.83% · institutions 56.04% · other public 38.01%
- Reappointment of Dr.Lakshmana Rao C.V. (DIN 06885453) who retires by rotation and, being eligible, offers himself, for reappointmentOrdinaryPromoters have an interest in it99.72% for0.28% against
Against: promoters 0.00% · institutions 0.30% · other public 0.64%
Turnout: all 56.98% · promoters 90.66% · institutions 56.04% · other public 38.01%
- Approval for payment of remuneration payable to Cost Auditors for the Financial Year 2021-22Ordinary99.98% for0.02% against
Against: promoters 0.00% · institutions 0.00% · other public 0.08%
Turnout: all 59.52% · promoters 99.98% · institutions 56.04% · other public 38.01%
- Modification of terms of Bonus in Employment Contract of Dr.Satyanarayana Chava (DIN 00211921), Executive Director and Chief Executive Officer of the CompanySpecialPromoters have an interest in it87.47% for12.53% against
Against: promoters 0.00% · institutions 26.79% · other public 0.60%
Turnout: all 40.57% · promoters 14.83% · institutions 72.92% · other public 38.01%
- Modification of terms of Bonus in Employment Contract of Mr.V.V.Ravi Kumar (DIN 01424180), Executive Director and Chief Financial Officer of the CompanySpecialPromoters have an interest in it91.80% for8.20% against
Against: promoters 0.00% · institutions 26.79% · other public 0.77%
Turnout: all 62.33% · promoters 94.57% · institutions 72.92% · other public 37.99%
- Modification of terms of Bonus in Employment Contract of Dr.Lakshmana Rao C.V. (DIN 06885453), Executive Director of the CompanySpecialPromoters have an interest in it91.65% for8.35% against
Against: promoters 0.00% · institutions 26.79% · other public 0.77%
Turnout: all 61.27% · promoters 90.66% · institutions 72.92% · other public 37.99%
- Reappointment of Mrs.Aruna Bhinge as Independent DirectorSpecial99.43% for0.57% against
Against: promoters 0.00% · institutions 2.38% · other public 0.05%
Turnout: all 59.02% · promoters 99.98% · institutions 54.07% · other public 38.01%
- Reappointment of Dr.Rajesh Koshy Chandy as Independent DirectorSpecial99.20% for0.80% against
Against: promoters 0.00% · institutions 3.36% · other public 0.04%
Turnout: all 59.02% · promoters 99.98% · institutions 54.07% · other public 38.01%
- Approval of Laurus Labs Employees Stock Option Scheme 2021Special90.86% for9.14% against
Against: promoters 0.00% · institutions 30.77% · other public 0.06%
Turnout: all 64.32% · promoters 99.98% · institutions 74.89% · other public 38.01%
- Approval for grant of options under Laurus Labs ESOP Scheme 2021 (ESOP Scheme 2021) to the eligible employees of the subsidiary companiesSpecial90.82% for9.18% against
Against: promoters 0.00% · institutions 30.77% · other public 0.22%
Turnout: all 64.32% · promoters 99.98% · institutions 74.89% · other public 38.01%
- Alteration of clauses of Articles of Association of the CompanySpecial99.91% for0.09% against
Against: promoters 0.00% · institutions 0.00% · other public 0.33%
Turnout: all 64.32% · promoters 99.98% · institutions 74.89% · other public 38.01%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
How mutual funds voted
Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it
Mutual fund votes, meeting of 2 Jul 2026, 14 fund houses so far (houses' deadline to file 15 Oct 2026)
Each resolution counts the houses whose vote was matched to it; the rest are listed last.
Adoption of the: (a) audited Standalone Financial Statements of the Company for the financial year ended March 31, 2026, the reports of Board of Directors and Auditors thereon (b) audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2026, the reports of Board of Directors and Auditors thereonMoreLess
14 for0 against- Aproval and ratification of the 1st interim dividend on equity shares @ Re. 0.80 per equity share paid for the financial year 2025-26.10 for0 against
- Aproval and ratification of the 2nd interim dividend on equity shares @ Re. 1.20 per share for the financial year 2025-26.10 for0 against
- Re-appointment of Mr. Krishna Chaitanya Chava (DIN: 06831883), a Director, who retires by rotation and, being eligible, offers himself, for re-appointment
Against Jio BlackRock Mutual Fund
- Jio BlackRock Mutual FundKrishna Chaitanya Chava, 35, is heading the Synthesis Business unit of the company. He has experience in strategy, skill workshops and marketing within the Indian pharma market. He has been on the board of the company since 25 April 2024 and has attended six of seven board meetings (86%) held in FY26. He retires by rotation. While his reappointment is in line with regulations, the company has five promoters on the board as executive directors, which is disproportionate for the size of business. This practice deters from attracting the right talent to the company. Given the high promoter representation on the board. We do not support the resolution.
13 for1 against - Re-appointment of Mrs. Soumya Chava (DIN: 06831892), a Director, who retires by rotation and, being eligible, offers herself, for re-appointment.
Against Jio BlackRock Mutual Fund
- Jio BlackRock Mutual FundMs. Soumya Chava, 39, is headed the Commercial Function (Supply Chain Management and Business Development) of the company. She has been on the board of the company since 25 April 2024 and has attended all seven board meetings (100%) held in FY26. She retires by rotation. While her reappointment is in line with regulations, the company has five promoters on the board as executive directors, which is disproportionate for the size of business. This practice deters from attracting the right talent to the company. Given the high promoter representation on the board. We do not support the resolution.
13 for1 against - Approval of the appointment of Dr. Shekhar Chintamani Mande (DIN: 10083454) as an Independent Director of the Company14 for0 against
- Approval of the appointment of Mrs. Sutapa Banerjee (DIN:02844650) as an Independent Director of the Company14 for0 against
- Approval of payment of remuneration to the Non-Executive Director(s) including Independent Director(s) of the Company
Against HSBC Mutual Fund, Jio BlackRock Mutual Fund
- HSBC Mutual FundA vote AGAINST this resolution is warranted because: • The approval will be valid till perpetuity and shareholders will not get to review the payments in the future.
- Jio BlackRock Mutual FundAt the July 2016 EGM, shareholders approved the payment of remuneration/commission not exceeding, in aggregate, 1% per annum of the company's net profits. During the period from July 2016 to March 2026, each independent director received remuneration of Rs. 2.0 mn per annum, while one foreign independent director was paid USD 40,000 per annum.The proposed commission is reasonable and in line with market practices. The commission will be paid in addition to sitting fees and reimbursement of expenses incurred for attending Board and Committee meetings. Between FY22 and FY26 the commission to Non-Executive Directors (including Independent Directors) ranged from 0.1% to 0.4% of standalone profit before tax, therefore the company has been judicious in the past with regard to their commission payouts.However, the company has not defined a tenure for payment of commission, and the resolution is effectively valid for perpetuity. We believe shareholders must get a chance to periodically approve such payments. Hence, we do not support the resolution.
12 for2 against - Approval of the remuneration payable to cost auditors for the financial year 2026-2714 for0 against
7 proposals not matched to one resolution
- 2) Ratify first interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each for FY26.1 for0 against
- 3) Ratify second interim dividend of Rs.1.2 per equity share of face value Rs. 2.0 each for FY26.1 for0 against
- Approve First Interim Dividend1 for0 against
- Approve remuneration of Rs. 550,000 to Sagar & Associates, as cost auditor for FY271 for0 against
- Approve Second Interim Dividend1 for0 against
- Ratify first interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each for FY262 for0 against
- Ratify second interim dividend of Rs.1.2 per equity share of face value Rs. 2.0 each for FY262 for0 against
Mutual fund votes, meeting of 26 Jun 2025, 30 fund houses
Each resolution counts the houses whose vote was matched to it; the rest are listed last.
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2025, the reports of Board of Directors and Auditors thereon29 for0 against
- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2025 and report of Auditors thereon.29 for0 against
- To approve and ratify the 1st interim dividend on equity shares @ Rs.0.40 per share already paid for the Financial Year 2024-25.22 for0 against
- To approve and ratify the 2nd interim dividend on equity shares @ Rs.0.80 per share already paid for the Financial Year 2024-25.22 for0 against
- To appoint a Director in place of Dr. Satyanarayana Chava (DIN: 00211921) who retires by rotation and, being eligible, offers himself, for re-appointment.
Against Angel One Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, PPFAS Mutual Fund
- Angel One Mutual FundGovernance concern: Excessive time commitments; Remuneration skewed in favour of the proposed appointee.
- Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: Excessive time commitments; Remuneration skewed in favour of Mr. Satyanarayana Chava.
- PPFAS Mutual FundExcessive time commitments; Skewed Remuneration
23 for6 against - To appoint a Director in place of Dr. C.V. Lakshmana Rao (DIN: 06885453) who retires by rotation and, being eligible, offers himself, for re-appointment.29 for0 against
- TO APPROVE THE REMUNERATION PAYABLE TO COST AUDITORS FOR THE FINANCIAL YEAR ENDING 2025-2626 for0 against
- TO APPROVE THE APPOINTMENT OF SECRETARIAL AUDITORS OF THE COMPANY
Against Angel One Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, PPFAS Mutual Fund
- Angel One Mutual FundNon-Disclosure of Basis of Recommendation/ Credentials of proposed Auditor.
- Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundNon-Compliant with Reg. 36 of SEBI (LODR) 2015: Non-Disclosure of Basis of Recommendation/ Credentials of proposed Auditor.
- PPFAS Mutual FundNon-Disclosure of Basis of Recommendation/ Credentials of proposed Auditor
24 for6 against - TO APPROVE RE-APPOINTMENT OF DR. SATYANARAYANA CHAVA (DIN: 00211921) AS AN EXECUTIVE DIRECTOR & CEO OF THE COMPANY
Against Angel One Mutual Fund, Bandhan Mutual Fund, Edelweiss Mutual Fund, Franklin Templeton Mutual Fund, Groww Mutual Fund, HSBC Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund, NJ Mutual Fund, PPFAS Mutual Fund, Unifi Mutual Fund
- Angel One Mutual FundGovernance concern: Excessive time commitments; No absolute cap on variable pay or total remuneration; Remuneration skewed in favour of proposed appointee.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: Excessive time commitments; No absolute cap on variable pay or total remuneration; Remuneration skewed in favour of proposed appointee.
- Franklin Templeton Mutual Fund, HSBC Mutual FundA vote AGAINST this resolution is warranted given the following concerns in executive's remuneration: • There is no absolute monetary cap on the commission element. Further, there are no disclosures on the threshold and target performance that he needs to achieve to determine the commission element. • The FY2025 pay of the executive compared to the median remuneration is deemed high compared to companies of similar size and scale. • The proposed pay is deemed higher than the remuneration of executive directors at peer companies, and not commensurate with size and scale of company's operations.
- Invesco Mutual Fund, NJ Mutual FundDr. Satyanarayana Chava was paid Rs. 230.6 mn as remuneration in FY25 (as clarified by the company). We estimate his FY26 remuneration at Rs. 263.5 mn (including profit linked commission). While his fixed pay will remain unchanged over the course of his tenure, the profit-linked commission component is not capped: therefore, as profitability increases, remuneration may be much higher over the course of his tenure. The company should cap his overall remuneration in absolute terms and disclose the performance parameters that govern his variable pay. The estimated remuneration is high for the size and complexity of business and not in line with peers. While we support his reappointment on the board, given the ambiguity around his overall remuneration over the course of his tenure, we do not support his proposed remuneration terms. We do not support the resolution.
- Nippon India Mutual FundGovernance Concern: Excessive time commitments and Skewed remuneration
- PPFAS Mutual FundExcessive time commitments; No absolute cap on variable pay or total remuneration; Skewed Remuneration
- Unifi Mutual FundDr. Satyanarayana Chava was paid Rs. 131.5 mn as remuneration in FY25. We estimate his FY26 remuneration at Rs. 263.5 mn (including profit linked commission). While his fixed pay will remain unchanged over the course of his tenure, the profit-linked commission component, at 2% of consolidated pre-tax profits, is not capped: therefore, as profitability increases, remuneration may be much higher over the course of his tenure. The company should cap the overall remuneration in absolute terms and disclose the performance parameters that govern variable pay. The estimated remuneration is high for the size and complexity of business and not in line with peers. While we support his reappointment on the board, given the ambiguity around his overall remuneration over the course of his tenure, we do not support his proposed remuneration terms. We do not support the resolution.
16 for13 against - TO APPROVE RE-APPOINTMENT OF MR. V.V. RAVI KUMAR (DIN: 01424180) AS AN EXECUTIVE DIRECTOR & CFO OF THE COMPANY
Against Angel One Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, PPFAS Mutual Fund
- Angel One Mutual FundGovernance concern: No absolute cap on variable pay or total remuneration.
- Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: No absolute cap on variable pay or total remuneration.
- PPFAS Mutual FundNo absolute cap on variable pay or total remuneration
23 for6 against - TO APPROVE MODIFICATION OF TERMS OF EMPLOYMENT CONTRACT OF DR. LAKSHMANA RAO CV, (DIN: 06885453) WHOLE-TIME DIRECTOR OF THE COMPANY
Against Angel One Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund, PPFAS Mutual Fund
- Angel One Mutual FundGovernance concern: No absolute cap on variable pay or total remuneration.
- Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: No absolute cap on variable pay or total remuneration.
- Nippon India Mutual FundGovernance Concern: Skewed Remuneration
- PPFAS Mutual FundNo absolute cap on variable pay or total remuneration
22 for7 against - TO APPROVE MODIFICATION OF TERMS OF EMPLOYMENT CONTRACT OF MR. KRISHNA CHAITANYA CHAVA, (DIN: 06831883) WHOLETIME DIRECTOR OF THE COMPANY
Against Angel One Mutual Fund, Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund, NJ Mutual Fund, PPFAS Mutual Fund, Unifi Mutual Fund, UTI Mutual Fund
- Angel One Mutual FundGovernance concern: No absolute cap on variable pay or total remuneration.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: No absolute cap on variable pay or total remuneration.
- Baroda BNP Paribas Mutual FundAlthough legally compliant there is no absolute cap on variable pay.
- Invesco Mutual Fund, NJ Mutual FundKrishna Chaitanya Chava received Rs. 19.0 mn as remuneration in FY25 (as clarified by the company). We estimate his remuneration as per revised terms at Rs. 46.2 mn, which includes a new profit-linked commission component of 0.5% of consolidated PBT. While the estimated remuneration is commensurate with the size of business, the commission component is uncapped, unlike the previous structure where the bonus was capped at 25% of salary. This is a deterioration in practice. The company must cap the profit linked commission in absolute terms and disclose the performance parameters that govern his variable pay. Further, we do not support the revision in his remuneration terms, given the high promoter representation on the board (five members of the promoter group). We do not support the resolution.
- Nippon India Mutual FundGovernance Concern: Skewed Remuneration
- PPFAS Mutual FundNo absolute cap on variable pay or total remuneration
- Unifi Mutual FundKrishna Chaitanya Chava is Dr. Satyanarayana Chava’s son and part of the promoter group. He received Rs. 18.4 mn as remuneration in FY25. The terms of his remuneration structure are being revised to include commission, which is currently set at 0.5% of consolidated pre-tax profits. We estimate his remuneration as per revised terms at Rs. 46.2 mn. While the estimated remuneration is commensurate with the size of business, the commission component is uncapped, unlike the previous structure where the bonus was capped at 25% of salary. This is a deterioration in practice. The company must cap the profit linked commission in absolute terms and disclose the performance parameters that govern variable pay. Further, we do not support the revision in his remuneration terms, and the high promoter representation on the board (five members of the promoter group). We do not support the resolution.
- UTI Mutual FundKrishna Chaitanya Chava received Rs. 19.0 mn as remuneration in FY25 (as clarified by the company). We estimate his remuneration as per revised terms at Rs. 46.2 mn, which includes a new profit-linked commission component of 0.5% of consolidated PBT. We do not support the resolution as the overall promoter and promoter family remuneration is on higher side.
16 for13 against - TO APPROVE MODIFICATION OF TERMS OF EMPLOYMENT CONTRACT OF MRS. SOUMYA CHAVA, (DIN: 06831892) WHOLE-TIME DIRECTOR OF THE COMPANY
Against Angel One Mutual Fund, Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Invesco Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund, Nippon India Mutual Fund, NJ Mutual Fund, PPFAS Mutual Fund, Unifi Mutual Fund, UTI Mutual Fund
- Angel One Mutual FundGovernance concern: No absolute cap on variable pay or total remuneration.
- Bandhan Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: No absolute cap on variable pay or total remuneration.
- Baroda BNP Paribas Mutual FundGiven the short association with the company and no absolute cap on variable pay.
- Invesco Mutual Fund, NJ Mutual FundMs. Soumya Chava received Rs. 12.4 mn as remuneration in FY25 (as clarified by the company). We estimate her remuneration as per revised terms at Rs. 39.7 mn, which includes a new profit-linked commission component of 0.5% of consolidated PBT. While the estimated remuneration is commensurate with the size of business, the commission component is uncapped, unlike the previous structure where the bonus was capped at 25% of salary. This is a deterioration in practice. The company must cap the profit linked commission in absolute terms and disclose the performance parameters that govern her variable pay. Further, we do not support the revision in her remuneration terms, given the high promoter representation on the board (five members of the promoter group). We do not support the resolution.
- Nippon India Mutual FundGovernance Concern: Skewed Remuneration
- PPFAS Mutual FundNo absolute cap on variable pay or total remuneration
- Unifi Mutual FundMs. Soumya Chava is Dr. Satyanarayana Chava’s daughter and part of the promoter group. She received Rs. 11.2 mn as remuneration in FY25. The terms of her remuneration structure are being revised to include commission, which is currently set at 0.5% of consolidated pre-tax profits. We estimate her remuneration as per revised terms at Rs. 39.7 mn. While the estimated remuneration is commensurate with the size of business, the commission component is uncapped, unlike the previous structure where the bonus was capped at 25% of salary. This is a deterioration in practice. The company must cap the profit linked commission in absolute terms and disclose the performance parameters that govern variable pay. Further, we do not support the revision in her remuneration terms, given the high promoter representation on the board (five members of the promoter group). We do not support the resolution.
- UTI Mutual FundMs. Soumya Chava received Rs. 12.4 mn as remuneration in FY25 (as clarified by the company). We estimate her remuneration as per revised terms at Rs. 39.7 mn, which includes a new profit-linked commission component of 0.5% of consolidated PBT. We do not support the resolution as the overall promoter and promoter family remuneration is on higher side.
16 for13 against
19 proposals not matched to one resolution
- Item 1, as a fund house numbered it1 for0 against
- Item 2, as a fund house numbered it1 for0 against
- Item 3, as a fund house numbered it1 for0 against
- Item 4, as a fund house numbered it1 for0 against
- Item 5, as a fund house numbered it1 for0 against
- Item 6, as a fund house numbered it1 for0 against
- Item 7, as a fund house numbered it1 for0 against
- Item 9, as a fund house numbered it
Against Taurus Mutual Fund
- Taurus Mutual FundUnder Dr. Chava’s leadership, Laurus Labs has witnessed significant growth across APIs, formulations, and CDMO verticals. The doubling of remuneration reflects the value creation and scale achieved under his stewardship. It is performance-linked and directly correlated to the company’s pre-tax profit growth—thus aligning his incentives with shareholders. The 2% profit-linked commission is inherently variable—if the company underperforms, payouts decline. The absence of a cap is common in entrepreneurial led companies and incentivizes sustained high performance. Moreover, the commission is based on pre-tax profits, ensuring rewards are paid only after operational success. Continuity of Vision and Execution: Dr. Chava is not only a promoter but the strategic architect behind Laurus’s diversification and global partnerships. Retaining such leadership with a competitive remuneration package is crucial, especially as Laurus competes with global CDMO firms for talent and innovation pipelines. Global Benchmarking Needed, Not Peer Limitation: The argument that his compensation is high relative to Indian peers may not hold, as Laurus Labs is increasingly operating in global markets, with growing R&D intensity and complex operations. Global peer benchmarks, especially in the pharma CDMO space, would be more appropriate than just Indian mid-cap comparisons.
0 for1 against - Item 10, as a fund house numbered it1 for0 against
- Item 11, as a fund house numbered it1 for0 against
- Item 12, as a fund house numbered it
Against Taurus Mutual Fund
- Taurus Mutual FundKrishna Chava has played a significant role in the company’s CDMO and formulations business. The proposed revision reflects increased scope, responsibilities, and delivery, and brings his compensation closer to market-aligned levels. The 0.5% profit-linked commission ensures that remuneration is closely tied to actual business performance. This replaces a salary-linked bonus and better aligns incentives with shareholder value creation. The payout is not guaranteed and fluctuates with profits—encouraging accountability. As a key member of the promoter group, Krishna Chava is central to the company’s long-term succession and execution strategy. Retaining core leadership through structured incentives is essential, especially in the context of a technically intensive and globally competitive pharma environment.
0 for1 against - Item 13, as a fund house numbered it
Against Taurus Mutual Fund
- Taurus Mutual FundMs. Soumya Chava’s revised remuneration of ₹39.7 mn reflects the growing responsibilities she has undertaken within Laurus Labs. The proposed structure is in line with compensation trends for executives managing strategic roles in high-growth pharma companies. The shift from a capped bonus to a profit-linked commission creates a direct correlation between business performance and pay. The 0.5% of consolidated pre-tax profits is modest, and since it is variable in nature, the payout is earned, not guaranteed. This ensures motivation to drive sustainable profitability. Again, as a member of the promoter group, Ms. Soumya Chava is deeply aligned with the long-term interests of shareholders. Incentivizing next-generation leadership within the promoter family ensures succession continuity, preserves institutional memory, and fosters stable strategic direction in a complex, globally competitive sector.
0 for1 against - 3) Ratify first interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each for FY25.1 for0 against
- 4) Ratify second interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each for FY25.1 for0 against
- Approve First Interim Dividend2 for0 against
- Approve remuneration of Rs. 550,000 to Sagar & Associates, as cost auditor for FY263 for0 against
- Approve Second Interim Dividend2 for0 against
- Ratify first interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each for FY254 for0 against
- Ratify second interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each for FY254 for0 against
6 earlier meetings
Mutual fund votes, meeting of 3 Oct 2024, 26 fund houses
- Appointment of Mr. Ramesh Subrahmanian (DIN: 02933019) as a Non-executive Independent Director of the Company
Against Bajaj Finserv Mutual Fund, Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Zerodha Mutual Fund
- Bajaj Finserv Mutual Fund, Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Zerodha Mutual FundNo concern on the merits of proposed appointee. Non-Compliant with SEBI (LODR) & Companies Act, 2013: Terms and Conditions of the Independent Directors not disclosed on the website.
20 for6 against
Mutual fund votes, meeting of 11 Jul 2024, 23 fund houses
Each resolution counts the houses whose vote was matched to it; the rest are listed last.
- To consider and adopt the audited Standalone FinancialnStatements of the Company for the Financial Year endednMarch 31, 2024, the reports of Board of Directors andnAuditors thereon2 for0 against
- To consider and adopt the audited Consolidated FinancialnStatements of the Company for the Financial Year endednMarch 31, 2024 and report of Auditors thereon.2 for0 against
- To approve and ratify the interim dividend on equity shares @nRs. 0.40 per share already paid for the Financial Year 2023-24.2 for0 against
- To approve and ratify the 2nd interim dividend on equitynshares @ Rs. 0.40 per share already paid for the Financial Yearn2023-24.2 for0 against
- To appoint a Director in place of Mr. V V Ravi Kumar (DINn01424180) who retires by rotation and, being eligible, offersnhimself, for re-appointment.17 for0 against
- TO APPROVE THE REMUNERATION PAYABLEnTO COST AUDITORS FOR THE FINANCIAL YEARnENDING 2024-252 for0 against
- APPOINTMENT OF Mr. KRISHNA CHAITANYAnCHAVA AS DIRECTOR2 for0 against
- APPOINTMENT OF MS. SOUMYA CHAVA ASnDIRECTOR2 for0 against
- TO APPROVE THE APPOINTMENT OF MR.nKRISHNA CHAITNANYA CHAVA (DIN 06831883)nAS EXECUTIVE DIRECTOR OF THE COMPANY2 for0 against
- TO APPROVE THE APPOINTMENT OF MS. SOUMYAnCHAVA (DIN 06831892) AS EXECUTIVE DIRECTORnOF THE COMPANY2 for0 against
- TO APPROVE THE APPOINTMENT OF MR.nKARNAM SEKAR AS INDEPENDENT DIRECTORnFOR A PERIOD OF 5 YEARS
Against JM Financial Mutual Fund
- JM Financial Mutual FundNo concern on the merits of proposed appointee. Non-Compliant with SEBI (LODR) & Companies Act, 2013: Terms and Conditions of the Independent Directors not disclosed on the website.
3 for1 against
42 proposals not matched to one resolution
- 1) Adoption of Audited Standalone Financial Statements for the year ended March 31, 2024 and the reports of the Directors and Auditors thereon.1 for0 against
- 10) Appoint Ms. Soumya Chava (DIN: 06831892) as Executive Director for five years from 25 April 2024 and fix her remuneration.1 for0 against
- 11) Appoint Karnam Sekar (DIN: 07400094) as Independent Director for five years from 25 April 2024, with an annual remuneration of Rs. 2 mn in addition to sitting fees.1 for0 against
- 2) Adoption of Audited Consolidated Financial Statements for the year ended March 31, 2024 and Auditors report thereon.1 for0 against
- 3) Ratify first interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each for FY24.1 for0 against
- 4) Ratify second interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each for FY24.1 for0 against
- 5) Reappoint V V Ravi Kumar (DIN 01424180) as Director, liable to retire by rotation.1 for0 against
- 6) Approve remuneration of Rs. 550,000 to Sagar & Associates, as cost auditor for FY25.1 for0 against
- 7) Appoint Krishna Chaitanya Chava (DIN: 06831883) as Director, liable to retire by rotation.1 for0 against
- 8) Appoint Ms. Soumya Chava (DIN: 06831892) as Director, liable to retire by rotation.1 for0 against
- 9) Appoint Krishna Chaitanya Chava (DIN: 06831883) as Executive Director for five years from 25 April 2024 and fix his remuneration.1 for0 against
- Accept Consolidated Financial Statements and Statutory Reports2 for0 against
- Accept Standalone Financial Statements and Statutory Reports2 for0 against
- Adoption of consolidated financial statements for the year ended 31 March 20243 for0 against
- Adoption of standalone financial statements for the year ended 31 March 20243 for0 against
- Appoint Karnam Sekar (DIN: 07400094) as Independent Director for five years from 25 April 2024, with an annual remuneration of Rs. 2 mn in addition to sitting fees3 for0 against
- Appoint Krishna Chaitanya Chava (DIN: 06831883) as Director, liable to retire by rotation
Against DSP Mutual Fund, Sundaram Mutual Fund
- DSP Mutual Fund, Sundaram Mutual FundKrishna Chaitanya Chava, 34, is heading the Synthesis Business unit of the Company. He has experience in strategy, skill workshops and marketing within the Indian pharma market. He completed his PGP MFAB from ISB, Hyderabad, master’s degree in mechanical engineering from North Carolina State University and bachelor’s degree in mechanical engineering from BITS Pilani, Dubai. While his appointment is in line with regulations, the company has three family members on the board as executive directors (and few in office of profit positions), which is disproportionate for the size of business. This practice deters from attracting the right talent to the company.
1 for2 against - Appoint Krishna Chaitanya Chava (DIN: 06831883) as Executive Director for five years from 25 April 2024 and fix his remuneration
Against DSP Mutual Fund, Sundaram Mutual Fund
- DSP Mutual Fund, Sundaram Mutual FundKrishna Chaitanya Chava’s estimated remuneration for FY25 is Rs. 21.9 mn. The proposed remuneration terms include fixed pay of Rs. 16 mn with an annual increment of 10%. Variable pay will be limited to 25% of fixed pay, based on the achievement of pre-defined EBITDA targets. We note that the proposed remuneration is commensurate with his responsibilities and is comparable with the peers. However, we do not support the resolution as it is linked to our decision on Resolution #7. The company must also disclose if other employees (that are not part of the promoter group) have been committed a 10% annual increment.
1 for2 against - Appoint Ms. Soumya Chava (DIN: 06831892) as Director, liable to retire by rotation
Against DSP Mutual Fund, Sundaram Mutual Fund
- DSP Mutual Fund, Sundaram Mutual FundMs. Soumya Chava, 38, was appointed as Executive Vice President in 2023 and headed the Commercial Function (Supply Chain Management and Business Development) of the Company. She has more than twelve years of experience in the Pharma Industry. She has completed her Bachelor of Pharmacy from Osmania University and master’s in clinical research and business administration from Campbell University. While her appointment is in line with regulations, the company has three family members on the board as executive directors (and few in office of profit positions), which is disproportionate for the size of business. This practice deters from attracting the right talent to the company.
1 for2 against - Appoint Ms. Soumya Chava (DIN: 06831892) as Executive Director for five years from 25 April 2024 and fix her remuneration
Against DSP Mutual Fund, Sundaram Mutual Fund
- DSP Mutual Fund, Sundaram Mutual FundMs. Soumya Chava’s estimated remuneration for FY25 is Rs. 14.2 mn. The proposed remuneration terms include fixed pay of Rs. 10.4 mn with an annual increment of 10%. Variable pay will be limited to 25% of fixed pay, based on the achievement of pre-defined EBITDA targets. It is commensurate with her responsibilities and is in line with the peers. However, we do not support the resolution as it is linked to our decision on Resolution #8. The company must also disclose if other employees (that are not part of the promoter group) have been committed a 10% annual increment.
1 for2 against Appointment of Mr. Krishna Chaitanya Chava having Director Identification Number 06831883, as Director of the Company whose period of office is liable to determination by retirement of directors by rotation u/s. 152 of the Companies Act, 2013.MoreLess
Against Invesco Mutual Fund
- Invesco Mutual FundKrishna Chaitanya Chava, 34, is heading the Synthesis Business unit of the Company. He has experience in strategy, skill workshops and marketing within the Indian pharma market. He completed his PGP MFAB from ISB, Hyderabad, master’s degree in mechanical engineering from North Carolina State University and bachelor’s degree in mechanical engineering from BITS Pilani, Dubai. While his appointment is in line with regulations, the company has three family members on the board as executive directors (and few in office of profit positions), which is disproportionate for the size of business. This practice deters from attracting the right talent to the company
14 for1 againstAppointment of Ms. Soumya Chava, having Director Identification Number 06831892, as Director of the Company whose period of office is liable to determination by retirement of directors by rotation u/s. 152 of the Companies Act, 2013.MoreLess
Against Invesco Mutual Fund
- Invesco Mutual FundMs. Soumya Chava, 38, was appointed as Executive Vice President in 2023 and headed the Commercial Function (Supply Chain Management and Business Development) of the Company. She has more than twelve years of experience in the Pharma Industry. She has completed her Bachelor of Pharmacy from Osmania University and master’s in clinical research and business administration from Campbell University. While her appointment is in line with regulations, the company has three family members on the board as executive directors (and few in office of profit positions), which is disproportionate for the size of business. This practice deters from attracting the right talent to the company
14 for1 against- Approve Appointment and Remuneration of Krishna Chaitanaya Chava as Executive Director
Against Franklin Templeton Mutual Fund, HSBC Mutual Fund
- Franklin Templeton Mutual FundA vote AGAINST this resolution is warranted because Krishna Chava's limited leadership experience of around seven years, raises concerns on his potential contribution to the board.
- HSBC Mutual FundA vote AGAINST this resolution is warranted because Krishna Chava's limited leadership experience of around seven years, raises concerns on his potential contribution to the board
0 for2 against - Approve Appointment and Remuneration of Soumya Chava as Executive Director2 for0 against
- Approve Interim Dividend2 for0 against
- Approve Remuneration of Cost Auditors2 for0 against
- Approve remuneration of Rs. 550,000 to Sagar & Associates, as cost auditor for FY253 for0 against
- Approve Second Interim Dividend2 for0 against
- Elect Krishna Chaitanya Chava as Director
Against Franklin Templeton Mutual Fund, HSBC Mutual Fund
- Franklin Templeton Mutual Fund, HSBC Mutual FundA vote AGAINST this resolution is warranted as Krishna Chaitanya Chava's limited leadership experience of around seven years, raises concerns on his potential contribution to the board.
0 for2 against - Elect Soumya Chava as Director2 for0 against
Ratification of remuneration of Rs. 5,50,000/- per annum and out of pocket and other expenses and GST at actuals payable to M/s. Sagar and Associates, as a Cost Auditor appointed by the Board of Directors of the Company, to conduct the audit of the cost records of the Company for the financial year 2023 - 24.MoreLess
15 for0 against- Ratify first interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each for FY243 for0 against
- Ratify second interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each for FY243 for0 against
- Reappoint V V Ravi Kumar (DIN 01424180) as Director, liable to retire by rotation3 for0 against
- Reelect V V Ravi Kumar as Director2 for0 against
- To approve and ratify the 2nd interim dividend on equity shares @ Rs. 0.40 per share already paid for the Financial Year 2023 - 24.15 for0 against
- To approve and ratify the interim dividend on equity shares @ Rs. 0.40 per share already paid for the Financial Year 2023 - 24.15 for0 against
To approve the appointment of Mr. Karnam Sekar having Director Identification Number 07400094, as Independent Director of the Company not liable to retire by rotation, for a first term of 5 (five) years with effect from April 25, 2024 i.e. up to April 24, 2029.MoreLess
Against Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Groww Mutual Fund, LIC Mutual Fund, Motilal Oswal Mutual Fund, Nippon India Mutual Fund, Zerodha Mutual Fund
- Bandhan Mutual Fund, Baroda BNP Paribas Mutual Fund, Groww Mutual Fund, LIC Mutual Fund, Motilal Oswal Mutual FundNo concern on the merits of proposed appointee. Non-Compliant with SEBI (LODR) & Companies Act, 2013: Terms and Conditions of the Independent Directors not disclosed on the website.
- Nippon India Mutual FundInadequate Disclosure
- Zerodha Mutual FundTerms and Conditions of the Independent Directors not disclosed on the website.
8 for7 againstTo approve the appointment of Mr. Krishna Chaitanaya Chava (DIN: 06831883) as Executive Director of the Company, whose office will be liable to determination by retirement by rotation, for a period of five (05) years effective from April 25, 2024 up to April 24, 2029 and including remuneration.MoreLess
Against Invesco Mutual Fund
- Invesco Mutual FundKrishna Chaitanya Chava’s estimated remuneration for FY25 is Rs. 21.9 mn. The proposed remuneration terms include fixed pay of Rs. 16 mn with an annual increment of 10%. Variable pay will be limited to 25% of fixed pay, based on the achievement of pre-defined EBITDA targets. We note that the proposed remuneration is commensurate with his responsibilities and is comparable with the peers. However, we do not support the resolution as it is linked to our decision on Resolution #7. The company must also disclose if other employees (that are not part of the promoter group) have been committed a 10% annual increment
14 for1 againstTo approve the appointment of Ms. Soumya Chava (DIN: 06831892) as Executive Director of the Company, whose office will be liable to determination by retirement by rotation, for a period of five (05) years effective from April 25, 2024 up to April 24, 2029 and including remuneration.MoreLess
Against Invesco Mutual Fund
- Invesco Mutual FundMs. Soumya Chava’s estimated remuneration for FY25 is Rs. 14.2 mn. The proposed remuneration terms include fixed pay of Rs. 10.4 mn with an annual increment of 10%. Variable pay will be limited to 25% of fixed pay, based on the achievement of pre-defined EBITDA targets. It is commensurate with her responsibilities and is in line with the peers. However, we do not support the resolution as it is linked to our decision on Resolution #8. The company must also disclose if other employees (that are not part of the promoter group) have been committed a 10% annual increment
14 for1 against- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2024 and report of Auditors thereon.15 for0 against
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2024, the reports of Board of Directors and Auditors thereon.15 for0 against
Mutual fund votes, meeting of 14 Jul 2023, 17 fund houses
Each resolution counts the houses whose vote was matched to it; the rest are listed last.
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023, the reports of Board of Directors and Auditors thereon16 for0 against
- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2023 and report of Auditors thereon.16 for0 against
- To approve and ratify the interim dividend on equity shares @ Rs. 0.80 per share already paid for the Financial Year 2022-23.15 for0 against
- To approve and ratify the 2nd interim dividend on equity shares @ Rs. 1.20 per share already paid for the Financial Year 2022-23.15 for0 against
- To appoint a Director in place of Dr. Satyanarayana Chava (DIN 00211921) who retires by rotation and, being eligible, offers himself, for re-appointment.
Against Motilal Oswal Mutual Fund, PGIM India Mutual Fund
- Motilal Oswal Mutual Fund, PGIM India Mutual FundCompliant with law. Governance concern: Remuneration skewed in favour of Mr. Satyanarayana Chava.
14 for2 against - To appoint a Director in place of Dr. Chunduru Venkata Lakshmana Rao (DIN 06885453) who retires by rotation and, being eligible, offers himself, for re-appointment16 for0 against
- To approve the remuneration payable to Cost Auditors for the financial year ending 2023-2416 for0 against
- To Approve the appointment of Ms. Soumya Chava as Head-Commercial
Against Franklin Templeton Mutual Fund, HSBC Mutual Fund, Nippon India Mutual Fund, SBI Mutual Fund, Sundaram Mutual Fund
- Franklin Templeton Mutual FundA vote AGAINST this resolution is warranted because the proposal is deemed a related-party-transaction and the proposed mandate may limit shareholders' rights to review and vote on the said transaction on a periodic basis.
- HSBC Mutual FundThe proposal is deemed a related-party-transaction and the proposed mandate may limit shareholders' rights to review and vote on the said transaction on a periodic basis.
- Nippon India Mutual FundRemuneration is high
- SBI Mutual Fund, Sundaram Mutual FundMs. Soumya Chava is the daughter of Dr. Satyanarayana Chava, ED & CEO, spouse of Chandrakanth Chereddi, Non-Executive Director, and sister of Krishna Chaitanya Chava, Executive Vice President, and BU Head-Synthesis. She has been serving as Director, Laurus Synthesis Pvt Ltd since 2021 and as Head CSR of Laurus Charitable Trust since 2022. Ms. Soumya Chava’ s proposed remuneration of Rs. 12.0 mn p.a. is high and not commensurate with her experience, nor is it comparable to the remuneration drawn by more experienced employees of the company. The company has not capped the other benefits that will be payable to Ms. Soumya Chava. Further, the proposed resolution is perpetual in nature. In 2017, Krishna Chaitanya Chava was appointed to an office of profit position with proposed remuneration of Rs 6.0 mn plus other benefits through a perpetual resolution. Since then, his remuneration has increased from Rs 5.2 mn in FY18 to Rs 15.6 mn in FY23; therefore, we expect that the actual payout to Ms. Soumya Chava may also exceed the stated amount of Rs. 12.0 mn per annum in the future.
11 for5 against
10 proposals not matched to one resolution
- Item 1, as a fund house numbered it1 for0 against
- Item 2, as a fund house numbered it1 for0 against
- Item 3, as a fund house numbered it
Against Taurus Mutual Fund
- Taurus Mutual FundMs. Soumya Chava is the daughter of Dr. Satyanarayana Chava, ED & CEO, spouse of Chandrakanth Chereddi, Non-Executive Director, and sister of Krishna Chaitanya Chava, Executive Vice President, and BU Head-Synthesis. She has been serving as Director, Laurus Synthesis Pvt Ltd since 2021 and as Head CSR of Laurus Charitable Trust since 2022. Ms. Soumya Chava’ s proposed remuneration of Rs. 12.0 mn p.a. is high and not commensurate with her experience, nor is it comparable to the remuneration drawn by more experienced employees of the company. The company has not capped the other benefits that will be payable to Ms. Soumya Chava. Further, the proposed resolution is perpetual in nature. In 2017, Krishna Chaitanya Chava was appointed to an office of profit position with proposed remuneration of Rs 6.0 mn plus other benefits through a perpetual resolution. Since then, his remuneration has increased from Rs 5.2 mn in FY18 to Rs 15.6 mn in FY23; therefore, we expect that the actual payout to Ms. Soumya Chava may also exceed the stated amount of Rs. 12.0 mn per annum in the future.
0 for1 against - Item 4, as a fund house numbered it1 for0 against
- Item 5, as a fund house numbered it1 for0 against
- Item 6, as a fund house numbered it1 for0 against
- Item 7, as a fund house numbered it1 for0 against
- Item 8, as a fund house numbered it1 for0 against
- Ratify first interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each for FY231 for0 against
- Ratify second interim dividend of Rs.1.2 per equity share of face value Rs. 2.0 each for FY231 for0 against
Mutual fund votes, meeting of 9 Mar 2023, 16 fund houses
- RE-APPOINTMENT OF DR. VENKATA LAKSHMANA RAO CHUNDURU (DIN 06885453) AS EXECUTIVE DIRECTOR OF THE COMPANY16 for0 against
Mutual fund votes, meeting of 30 Jun 2022, 18 fund houses
Each resolution counts the houses whose vote was matched to it; the rest are listed last.
- To consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2022, the reports of Board of Directors and Auditors thereon18 for0 against
- To consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2022 and report of Auditors thereon.18 for0 against
- To approve and ratify the 1st interim dividend on equity shares Rs. 0.80 per share already paid for the Financial Year 2021-22.13 for0 against
- To approve and ratify the 02nd interim dividend on equity shares Rs. 1.20 per share already paid for the Financial Year 2021-22.13 for0 against
- To appoint a Director in place of Mr. Chandrakanth Chereddi (DIN 06838798) who retires by rotation and, being eligible, offers himself, for re-appointment.18 for0 against
- To appoint a Director in place of Mr. V V Ravi Kumar (DIN 01424180) who retires by rotation and, being eligible, offers himself, for re-appointment.18 for0 against
- Reappointment of Statutory Auditor
Against Kotak Mahindra Mutual Fund, Nippon India Mutual Fund
- Kotak Mahindra Mutual FundNon-Compliant with Regulation 36(5) of SEBI LODR. The company has not disclosed proposed audit fee.
- Nippon India Mutual FundInadequate disclosure
15 for2 against - TO APPROVE THE REMUNERATION PAYABLE TO COST AUDITORS FOR THE FINANCIAL YEAR ENDING 2022-23
Against Kotak Mahindra Mutual Fund
- Kotak Mahindra Mutual FundThough compliant with law. The company has not disclosed portion of the turnover that is subject to Cost Audit. The cost audit fee is also significantly lower than fee suggested by the ICAI.
17 for1 against - REAPPOINTMENT OF Dr. MALEMPATI VENUGOPALA RAO AS INDEPENDENT DIRECTOR FOR A FURTHER PERIOD OF 2 YEARS
Against Nippon India Mutual Fund
- Nippon India Mutual FundShareholder's approval not obtained on time for reappointment of director
17 for1 against - REAPPOINTMENT OF Dr. RAVINDRANATH KANCHERLA AS INDEPENDENT DIRECTOR FOR A FURTHER PERIOD OF 5 YEARS
Against Nippon India Mutual Fund
- Nippon India Mutual FundShareholder's approval not obtained on time for reappointment of director
17 for1 against
9 proposals not matched to one resolution
- 3) Ratify first interim dividend of Rs.0.8 per equity share for FY22.1 for0 against
- 4) Ratify second interim dividend of Rs.1.2 per equity share for FY22.1 for0 against
- Approve Deloitte Haskins & Sells LLP, Chartered Accountants as Auditors and Authorize Board to Fix Their Remuneration1 for0 against
- Approve First Interim Dividend1 for0 against
- Approve Second Interim Dividend1 for0 against
- Ratify first interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each for FY222 for0 against
- Ratify second interim dividend of Rs.1.2 per equity share of face value Rs. 2.0 each for FY222 for0 against
- TO APPROVE AND RATIFY THE 1 INTERIM DIVIDEND ON EQUITY SHARES AT THE RATE 0.80 PER SHARE ALREADY PAID FOR THE FY 2021 22.1 for0 against
- TO APPROVE AND RATIFY THE 2 INTERIM DIVIDEND ON EQUITY SHARES AT THE RATE 1.20 PER SHARE ALREADY PAID FOR THE FY 2021 22.1 for0 against
Mutual fund votes, meeting of 15 Jul 2021, 11 fund houses
Each resolution counts the houses whose vote was matched to it; the rest are listed last.
- Adoption of the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2021, the reports of Board of Directors and Auditors thereon11 for0 against
- Adoption of the audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2021 and report of Auditors thereon11 for0 against
- Approval and ratification of the 1st interim dividend on equity shares @ Rs.0.80 already paid for FY 217 for0 against
- Approval and ratification of the 2nd interim dividend on equity shares @ Rs.0.40 already paid for FY 217 for0 against
- Approval and ratification of 3rd interim dividend on equity shares @ Rs.0.80 for the FY217 for0 against
- Reappointment of Dr.Satyanarayana Chava (DIN 00211921) who retires by rotation and, being eligible, offers himself for reappointment10 for0 against
- Reappointment of Dr.Lakshmana Rao C.V. (DIN 06885453) who retires by rotation and, being eligible, offers himself, for reappointment10 for0 against
- Approval for payment of remuneration payable to Cost Auditors for the Financial Year 2021-227 for0 against
- Modification of terms of Bonus in Employment Contract of Dr.Satyanarayana Chava (DIN 00211921), Executive Director and Chief Executive Officer of the Company
Against Bank of India Mutual Fund, HSBC Mutual Fund, Tata Mutual Fund
- Bank of India Mutual Fund, Tata Mutual FundThe bonus cap of 120% of annual salary for Dr. Satyanarayana Chava is being removed, which is a deterioration in remuneration practices. Dr. Satyanarayana Chava’s FY21 remuneration aggregated Rs. 264. 4 mn (including bonus for the year). The increase in FY21 remuneration has outpaced the growth in employee remuneration: Satyanarayana Chava’s FY21 remuneration is 638. 1x the median employee remuneration. Although we recognize that the remuneration is linked with the achievement of EBIDTA, we believe there needs to be a reasonable cap on overall remuneration. While the company has confirmed that the managerial remuneration for FY21 will be less than 3. 5% of the PBT, the remuneration payable for FY21 (after considering the bonus payable for FY21) is high for the size of the business and there is no clarity on the maximum remuneration payable to the directors for the remainder of their term. Further, the board must consider diversifying its performance targets to include non-financial parameters that qualitatively define performance.
- HSBC Mutual FundA vote AGAINST this resolution is warranted because: - The Company has not disclosed the EBITDA targets on which the bonus payouts are based. Therefore, it is not possible to assess whether the targets set are sufficiently stretching. Insuch a scenario, removal of the upper cap on the bonus might lead to discretionary payouts to the Executive Directors. - The salaries of the Executive Directors are aggressively positioned compared to its peers. Given that their remuneration structure includes a high fixed pay element, the need to remove the ceiling from variable pay is unclear.
7 for3 against1 abstained
- Modification of terms of Bonus in Employment Contract of Mr.V.V.Ravi Kumar (DIN 01424180), Executive Director and Chief Financial Officer of the Company
Against Bank of India Mutual Fund, HSBC Mutual Fund, Tata Mutual Fund
- Bank of India Mutual Fund, Tata Mutual FundThe bonus cap of 60% of annual salary for V V Ravi Kumar is being removed, which is a deterioration in remuneration practices. V V Ravi Kumar’s FY21 remuneration aggregated Rs. 60. 4 mn (including bonus for the year). The increase in FY21 remuneration has outpaced the growth in employee remuneration: V V Ravi Kumar’s FY21 remuneration is 145. 8x the median employee remuneration. Although we recognize that the remuneration is linked with the achievement of EBIDTA, we believe there needs to be a reasonable cap on overall remuneration. While the company has confirmed that the managerial remuneration for FY21 will be less than 3. 5% of the PBT, the remuneration payable for FY21 (after considering the bonus payable for FY21) is high for the size of the business and there is no clarity on the maximum remuneration payable to the directors for the remainder of their term. Further, the board must consider diversifying its performance targets to include non-financial parameters that qualitatively define performance.
- HSBC Mutual FundA vote AGAINST this resolution is warranted because: - The Company has not disclosed the EBITDA targets on which the bonus payouts are based. Therefore, it is not possible to assess whether the targets set are sufficiently stretching. Insuch a scenario, removal of the upper cap on the bonus might lead to discretionary payouts to the Executive Directors. - The salaries of the Executive Directors are aggressively positioned compared to its peers. Given that their remuneration structure includes a high fixed pay element, the need to remove the ceiling from variable pay is unclear.
7 for3 against1 abstained
- Modification of terms of Bonus in Employment Contract of Dr.Lakshmana Rao C.V. (DIN 06885453), Executive Director of the Company
Against Bank of India Mutual Fund, HSBC Mutual Fund, Tata Mutual Fund
- Bank of India Mutual Fund, Tata Mutual FundThe bonus cap of 60% of annual salary for Dr. Lakshmana Rao C V is being removed, which is a deterioration in remuneration practices. Dr. Lakshmana Rao C V’s FY21 remuneration aggregated Rs. 38. 9 mn (including bonus for the year). The increase in FY21 remuneration has outpaced the growth in employee remuneration: Dr. Lakshmana Rao C V’s FY21 remuneration is 93. 9x the median employee remuneration. Although we recognize that the remuneration is linked with the achievement of EBIDTA, we believe there needs to be a reasonable cap on overall remuneration. While the company has confirmed that the managerial remuneration for FY21 will be less than 3. 5% of the PBT, the remuneration payable for FY21 (after considering the bonus payable for FY21) is high for the size of the business and there is no clarity on the maximum remuneration payable to the directors for the remainder of their term. Further, the board must consider diversifying its performance targets to include non-financial parameters that qualitatively define performance.
- HSBC Mutual FundA vote AGAINST this resolution is warranted because: - The Company has not disclosed the EBITDA targets on which the bonus payouts are based. Therefore, it is not possible to assess whether the targets set are sufficiently stretching. Insuch a scenario, removal of the upper cap on the bonus might lead to discretionary payouts to the Executive Directors. - The salaries of the Executive Directors are aggressively positioned compared to its peers. Given that their remuneration structure includes a high fixed pay element, the need to remove the ceiling from variable pay is unclear.
7 for3 against1 abstained
- Reappointment of Mrs.Aruna Bhinge as Independent Director10 for0 against
1 abstained
- Reappointment of Dr.Rajesh Koshy Chandy as Independent Director10 for0 against
1 abstained
- Approval of Laurus Labs Employees Stock Option Scheme 2021
Against Axis Mutual Fund, Bank of India Mutual Fund
- Axis Mutual FundThe aggregate number of ESOPs to be granted will not exceed 1.0 mn equity shares upon exercise representing ~0.2% of the current issued capital. The exercise price shall be at 25% discount to fair market value on the date of the grant which represents a significant discount to the current market price of Rs. 625.6. Further, the vesting of the ESOPs will be tenure based and not performance based. We do not favour ESOP schemes where the options are granted at a significant discount to market price or where there is no clarity on the performance metrics for vesting. ESOPs are ‘pay at risk’ options that employees accept at the time of grant, which is protected if the ESOPs are issued at significant discount to the market price
- Bank of India Mutual FundThe aggregate number of ESOPs to be granted will not exceed 1. 0 mn equity shares upon exercise representing ~0. 2% of the current issued capital. The exercise price shall be at 25% discount to fair market value on the date of the grant which represents a significant discount to the current market price of Rs. 625. 6. Further, the vesting of the ESOPs will be tenure based and not performance based. We do not favour ESOP schemes where the options are granted at a significant discount to market price or where there is no clarity on the performance metrics for vesting. ESOPs are ‘pay at risk’ options that employees accept at the time of grant, which is protected if the ESOPs are issued at significant discount to the market price.
8 for2 against - Approval for grant of options under Laurus Labs ESOP Scheme 2021 (ESOP Scheme 2021) to the eligible employees of the subsidiary companies
Against Axis Mutual Fund, Bank of India Mutual Fund
- Axis Mutual Fund, Bank of India Mutual FundThe company proposes to extend the ESOP 2021 Scheme to the employees of its subsidiary companies. Our decision on this resolution is linked to resolution #14.
8 for2 against - Alteration of clauses of Articles of Association of the Company10 for0 against
13 proposals not matched to one resolution
- Approve and ratify third interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each3 for0 against
- Approve remuneration of Rs. 550,000 payable to Sagar & Associates, cost auditors for FY213 for0 against
- Ratify first interim dividend of Rs.0.8 per equity share of face value Rs. 2.0 each3 for0 against
- Ratify second interim dividend of Rs.0.4 per equity share of face value Rs. 2.0 each3 for0 against
- TO APPOINT A DIRECTOR IN PLACE OF DR. LAKSHMANA RAO C V (DIN 06885453) WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF, FOR RE APPOINTMENT.1 for0 against
- TO APPOINT A DIRECTOR IN PLACE OF DR. SATYANARAYANA CHAVA (DIN 00211921) WHO RETIRES BY ROTATION AND, BEING ELIGIBLE, OFFERS HIMSELF, FOR RE APPOINTMENT.1 for0 against
- TO APPROVE AND RATIFY THE 1 INTERIM DIVIDEND ON EQUITY SHARES RS.0.80 ALREADY PAID FOR FY21.1 for0 against
- TO APPROVE AND RATIFY THE 2 INTERIM DIVIDEND ON EQUITY SHARES RS. 0.40 ALREADY PAID FOR FY21.1 for0 against
- TO APPROVE AND RATIFY THE 3 INTERIM DIVIDEND ON EQUITY SHARES RS. 0.80 FOR THE FY21.1 for0 against
- TO APPROVE THE REMUNERATION PAYABLE TO SAGAR AND ASSOCIATES AS COST AUDITORS FOR THE FY ENDING 2021 22.1 for0 against
To Authorize Board of Directors to create, offer and grant such number of employee stock options as may be decided by the Board within the overall limit of number of Stock Options under Laurus Labs Employees Stock Option Scheme, 2021 (“ESOP Scheme 2021”) to the present and / or future permanent employees of the subsidiary companies of the Company working in India or abroad and / or directors (including whole-time directors) of the subsidiary companies of the Company in India or aboard and any other individuals / entities as allowed under applicable rules, regulations, guidelines and laws (hereinafter referred to as “employees” or “said employees”) as per the terms and conditions of ESOP Scheme 2021 and as may from time to time be allowed under prevailing laws, rules and regulations, and/ or amendments thereto from time to time, on such terms and conditions as may be decided by the boardMoreLess
1 for0 againstTo Authorize Board of Directors to create, offer, issue and allot at any time to or for the benefit of such person(s) who are in the employment of the Company, including Directors of the Company whether whole time or otherwise whether working in India or out of India, under a Scheme titled “LAURUS LABS EMPLOYEES STOCK OPTION SCHEME 2021” (hereinafter referred as the “ESOP Scheme, 2021” or “Scheme”), options exercisable into equity shares being not more than 1,000,000 (One Million only) equity shares of ` 2 each of the Company at an exercise price of 25% discount on the Fair Market Value of Share on the date of Grant of Options under ESOP Scheme 2021, in one or more tranches and on such terms and conditions as may be fixed or determined by the Board/Committee in accordance with the provisions of the Companies Act 2013 or SBEB Regulations or other provisions of the laws as may be prevailing and applicable at that time, each option granted being exercisable for one equity share of the CompanyMoreLess
1 for0 against- To remove Clause 49A of Articles of Association of the Company1 for0 against
Each fund house counted once, from its own disclosure; the reasons are its own words.
Tax disputes
Reported in the filing for the quarter to Sep 2026.
- Tax disputePr. Commissioner of Income Tax-4, HyderabadSince 21 Aug 2025The current status remains the same as in the previous quarter.
At the filing before: Pending with the High Court of Telangana with ITA No. 201/Hyd/2024. Facts of the case: Disallowance of deduction under Section 35(2AB) & Section 14A of the Income Tax Act for AY 2016-17 - Amount involved is INR 5,82,33,400/-.MoreLess
- Tax disputePr. Commissioner of Income Tax-4, HyderabadSince 21 Aug 2025The current status remains the same as in the previous quarter.
At the filing before: Pending with the High Court of Telangana with ITA No. 121/Hyd/2024. Facts of the case: Disallowance of Sec 32AD of the Income Tax Act - Investment Allowance (Unit setup in backward areas) for AY 2016-17 - Amount involved is INR 11,16,50,605/-.MoreLess
- Tax disputePr. Commissioner of Income Tax-4, HyderabadSince 21 Aug 2025The current status remains the same as in the previous quarter.
At the filing before: Pending with the High Court of Telangana with ITA No. 202/Hyd/2024. Facts of the case: Disallowance of deduction under Section 35(2AB) & Section 14A of the Income Tax Act for AY 2017-18 - Amount involved is INR 9,63,04,490/-.MoreLess
- Tax disputePr. Commissioner of Income Tax-4, HyderabadSince 21 Aug 2025The current status remains the same as in the previous quarter.
At the filing before: Pending with the High Court of Telangana with ITA No. 203/Hyd/2024. Facts of the case: Disallowance of deduction under Section 35(2AB) of the Income Tax Act for AY 2018-19 - Amount involved is INR 4,88,56,363/-.MoreLess
- Tax disputeCommissioner of Service Tax, HyderabadSince 1 Mar 2017The current status remains the same as in the previous quarter.
At the filing before: Pending with CESTAT, Hyderabad Case No. Service Tax/0030708/2017. Facts of the case: Export of services under Scientific and Technical Consultancy Services treating as domestic service under POP Rule 4 for FY 2012 to FY 2015 - Amount involved is INR 4,98,88,820/-.MoreLess
- Tax disputeCommissioner of Service Tax, HyderabadSince 12 Mar 2020The current status remains the same as in the previous quarter.
At the filing before: Pending with CESTAT, Hyderabad Case No. Service Tax/0030035/2021. Facts of the case: Export of services under Scientific and Technical Consultancy Services treating as domestic service under POP Rule 4 for FY 2015-16 - FY 2017-18_Q1 - Amount involved is INR 8,19,09,780/-.MoreLess
- Tax disputeCommissioner of Customs, HyderabadSince 31 Dec 2019The current status remains the same as in the previous quarter.
At the filing before: Pending with CESTAT, Hyderabad Case No. Customs/0030028/2021. Facts of the case: Demand of Customs duty on Duty Scrips under Focus Product Scheme Section 28AAA for FY 2011-12 - Amount involved is INR 5,99,42,915/-.MoreLess
- Tax disputeTSSTAT, HyderabadSince 31 Dec 2014The current status remains the same as in the previous quarter.
At the filing before: Pending with Telangana ADC, Punjagutta, Hyderabad Apeal No. PV/284/2014-15. Facts of the case: Disallowance of input tax on Sales to SEZ which are taxable under CST ACt for FY 2013-14 - Amount involved is INR 42,50,876/-.MoreLess
3 more
- Tax disputeAPSTAT, VishakapatnamSince 26 Dec 2018The current status remains the same as in the previous quarter.
At the filing before: Pending with AP VAT Tribunal, Vishakapatnam, Ref No. 324/2017 & DC Order No 2148 and 197/2018 & DC Order No 2149. Facts of the case: Disallowance of input tax on Sales to SEZ which are taxable under CST Act for FY 2014-15, FY 2015-16 - Amount involved is INR 35,66,447/-.MoreLess
- Tax disputeCommissioner of Service Tax, HyderabadSince 13 Feb 2025The current status remains the same as in the previous quarter.
At the filing before: Pending with CESTAT, Hyderabad Order No: 03/2024-25 - Adjn (JC)ST-HYD. Facts of the case: Tax demand on Irregular Availment of Service Tax_ Non-Executive Directors RCM under service tax not paid for FY 2013-14, FY 2014-15 - Amount involved is INR 20,01,709/-.MoreLess
- Tax disputeCommissioner of Customs, GunturSince 27 Jul 2026
Pending with Commissioner of Customs (Appeals), Guntur File No: 14/2026 & Letter bearing No. VSEZ-VRM0J(DBK)/9/2023-SEZ Vizag. Facts of the case: Refund application claimed for INR 6,81,59,280/- whereas department disallowed part of the amount for the year FY 2022-23 - Amount involved is INR 3,84,49,838/-.MoreLess
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- Yes
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- Yes
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.